RECITALSResearch License and Option Agreement • January 15th, 1999 • Abgenix Inc • Biological products, (no disgnostic substances) • California
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Research License and Option Agreement • September 9th, 2020 • Codiak BioSciences, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Research License and Option Agreement (“Agreement”) is effective as of June 17, 2020 (“Effective Date”) made by and between CODIAK BIOSCIENCES, INC. a Delaware corporation having offices at 35 CambridgePark Drive, Suite 500, Cambridge, MA 02140 (“Codiak”), and SAREPTA THERAPEUTICS, INC., a Delaware corporation having offices at 215 First Street, Cambridge, MA 02142 (“Sarepta”). Each of Codiak and Sarepta may be referred to in this Agreement individually as a “Party” or together as the “Parties.”
RESEARCH LICENSE AND OPTION AGREEMENTResearch License and Option Agreement • December 19th, 2008 • Nitromed Inc • Pharmaceutical preparations • New York
This Research License and Option Agreement (this “Agreement”) is made effective as of June 11, 2008 (the “Effective Date”), by and between Archemix Corp, a Delaware corporation with offices at 300 Third Street, Cambridge, MA 02142 (“Archemix”), and Ribomic, Inc., a corporation organized under the laws of Japan with offices at Shirokanedai Usui Building, 3-16-13 Shirokanedai, Minato-ku, Tokyo 108-0071 Japan (“Ribomic”). Archemix and Ribomic are each sometimes hereinafter referred to individually as a “Party” and collectively as the “Parties.”
RESEARCH, LICENSE AND OPTION AGREEMENTResearch, License and Option Agreement • August 15th, 2016 • Wave Life Sciences Ltd. • Pharmaceutical preparations • New York
This research, license and option agreement (the “Agreement”) is entered into as of May 5th, 2016 (the “Effective Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, NY 10017 (“Pfizer”) and WAVE Life Sciences Ltd., a Singapore corporation having a principal place of business at 733 Concord Avenue, Cambridge, MA 02138 (“Wave”). Pfizer and Wave may each be referred to herein individually as a “Party” and collectively as the “Parties.”
